1 Min Read
* ALLIGATOR BIOSCIENCE CONTRACTS THERADEX ONCOLOGY AS CLINICAL CRO FOR THE UPCOMING ATOR-1015 PHASE I STUDY
* STUDY IS EXPECTED TO COMMENCE IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.